https://www.selleckchem.com/pr....oducts/vafidemstat.h
Twelve and 10 TT patients were dose escalated at the second and third cycles, respectively; 16 CT patients were dose escalated at the second and third cycles. Leukopenia, but not febrile neutropenia, was genotype and dose dependent and increased in patients with CT and TT genotypes as their dose was increased. However, the third-cycle leukopenia rates were comparable to patients with the CC genotype receiving standard-dose epirubicin. Pharmacogenetically guided epirubicin dosing is well tolerated and allowed dose escalation without
Like
Comment
Share
